Founders

Fimbrion Therapeutics, Inc. is a life sciences company based in St. Louis, MO founded in 2012 from intellectual property licensed from Washington University. Fimbrion’s mission is to discover, develop, and commercialize antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including antibiotic-resistant strains.

 
 
hultgren.jpg

Scott J. Hultgren, PhD
Professor of Molecular Microbiology and Director, Center for Women's Infectious Disease Research, Washington University School of Medicine

  • 297 Publications in Biological, Biochemical and Biophysical Sciences, as well as Infectious Diseases, Chemistry, and Drug Design
  • Member of the National Academy of Sciences
  • Member of the National Academy of Medicine
  • 15 US Granted Patents Including the Mannoside Technology
  • Nobel Fellow, Luminary and 2nd Century Award Winner
 
janetka350.jpg

James W. Janetka, PhD
Associate Professor of Biochemistry & Molecular Biophysics
Adjunct Professor of Chemistry, Washington University School of Medicine

       • 50 Publications in Synthetic Organic and Medicinal Chemistry, Biochemistry, Oncology, and Infectious Diseases
       • 20 US Granted Patents Including the Mannoside Technology
       • Accomplished Medicinal Chemist with Drug Discovery and Development Experience at Vertex and AstraZeneca

 
_MG_3714-2.jpg

Thomas M. Hooton, MD
Professor of Clinical Medicine, University of Miami Miller School of Medicine and Chief of Medicine, Miami VA Healthcare System

  • Clinical Director of the Infectious Diseases Division and Medical Director of Infection Control and Occupational Health, University of Miami Miller School of Medicine
  • 220 Publications in UTI, STI, Antimicrobial Stewardship, and other areas of Infectious Diseases
  • Key Opinion Leader on UTI